CTD Holdings, Inc. , a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that it has amended its agreement with Medical Need Europe such that MNE will be the exclusive distributor in Europe of Trappsol Cyclo and any new cyclodextrin-based Orphan Drug Designated treatments that CTD may develop in the future. MNE, which is based in Stockholm, Sweden, currently is the exclusive European distributor of CTD's orphan drug designated Trappsol Cyclo for the treatment of Niemann-Pick Type C, a rare and fatal disease found primarily in children.
http://ift.tt/1F5WEwS
http://ift.tt/1F5WEwS
No comments:
Post a Comment